Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284314 | 0.84 | BAZ2B (0.41) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL2085459 | 0.80 | BAZ2B (0.41) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL880222 | 0.72 | BAZ2B (0.47) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL12414587 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL15668445 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL24762447 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL19214670 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL433905 | 0.68 | BAZ2B (0.49) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL3715486 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 | |
| SCHEMBL5166278 | 0.68 | BAZ2B (0.44) | BAZ2BHTTHPGDNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201826-A1 | CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF | SOTZING GREGORY A | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201826-A1 | CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF | MPST, TST, PNMT | BAZ2B 2925/4885HTT 730/4885HPGD 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.